Percutaneous coronary intervention of severely calcified lesions has historically been associated with major adverse cardiac event (MACE) rates as high as 30%. In the ORBIT II (Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions) trial, treatment of de novo severely calcified lesions with the Diamondback 360 Coronary Orbital Atherectomy System (OAS) resulted in low rates of procedural and 30-day adverse ischemic events. The long-term results from this trial have not been reported. We sought to determine the 1-year outcomes after orbital atherectomy of severely calcified coronary lesions. ORBIT II was a single-arm trial enrolling 443 subjects at 49 US sites with severely calcified lesions usually excluded from randomized trials. OAS utilizes a centrifugal differential sanding mechanism of action for plaque modification prior to stent implantation. After OAS drug-eluting stents were implanted in 88.2% of the patients. The primary safety end point was 30-day MACE, the composite of cardiac death, myocardial infarction, or target vessel revascularization [TVR]. The present analysis reports the 1-year follow-up results from ORBIT II. One-year data were available in 433 of 443 patients (97.7%), with median follow-up time of 16.7 months. The 1-year MACE rate was 16.4%, including cardiac death (3.0%), myocardial infarction (9.7%), and target vessel revascularization (5.9%). The 1-year target lesion revascularization rate was 4.7%, and stent thrombosis occurred in 1 patient (0.2%). Independent predictors of 1-year MACE and target vessel revascularization were diameter stenosis at baseline and the use of bare-metal stents. In patients with severely calcified lesions who underwent percutaneous coronary intervention, the use of OAS was associated with low rates of 1-year adverse ischemic events compared with historical controls. This finding has important clinical implications for the selection of optimum treatment strategies for patients with severely calcified lesions. 
Despite advances in technology, percutaneous coronary intervention (PCI) of severely calcified coronary lesions remains a challenge. Contemporary studies have shown that the presence of moderate or severe coronary calcification at the target lesion is associated with a substantial increase in death, myocardial infarction (MI), stent thrombosis, and need for revascularization. 1e6 Coronary calcification is frequent, with about 1/3 of the lesions treated by PCI presenting with a substantial amount of calcification angiographically. 1 Current therapeutic options to manage calcified lesions (e.g., cutting/scoring balloons and rotational atherectomy) are associated with a high rate of restenosis and stent failure at long-term follow-up. 5 Recently, the ORBIT II (Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions) trial demonstrated favorable procedural and 30-day outcomes with the Diamondback 360 Coronary Orbital Atherectomy System (OAS) (Cardiovascular Systems, Inc., St. Paul, Minnesota) in the treatment of severely calcified lesions, resulting in its Food and Drug Administration (FDA) approval. 7 Whether the beneficial effects of this device seen at 30 days translate into favorable 1-year outcomes is not known. We report the prespecified analysis of the 1-year outcomes from the ORBIT II pivotal trial.
Methods
The design and initial results of ORBIT II have been published previously. 7 In brief, ORBIT II was a prospective, multicenter, nonblinded, single-arm clinical trial that enrolled patients with de novo severely calcified coronary lesions who underwent PCI. Key study inclusion criteria included: (1) 4.0 mm with a stenosis !70% and <100% or a stenosis !50% and <70% with evidence of clinical ischemia through positive stress test, fractional flow reserve value 0.8, or intravascular ultrasound (IVUS) minimum lumen area 4.0 mm 2 ; (2) target lesion length 40 mm; and (3) imaging evidence of severe calcium at the lesion site based on the angiographic presence of radio-opacities noted without cardiac motion before contrast injection involving both sides of the arterial wall in at least 1 location, total length of calcium of !15 mm and extending partially into the target lesion, or presence of !270 of calcium at 1 cross-section through IVUS. Patients were excluded if (1) the target vessel had a stent from a previous PCI unless the stent was on a different branch than the target lesion and was implanted >30 days before with no >30% in-stent restenosis; (2) recent MI (defined as creatine kinase-MB [CK-MB] >1Â upper limit of laboratory normal [ULN] within 30 days of the index procedure); and (3) evidence of current left ventricular ejection fraction 25%. The ORBIT II trial conformed to ethical guidelines of the Declaration of Helsinki, and study participants provided informed consent.
The coronary OAS uses a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands laterally through centrifugal force (up to a maximum orbit diameter for a given rotational speed) resulting in a differential sanding of coronary calcification. Two OAS configurations were used in the ORBIT II trial, pneumatic OAS and electric OAS, with crown diameter ranging from 1.25 up to 2.00 mm. Detailed description of OAS mechanism of action can be found elsewhere. 8, 9 The use of other adjunctive devices, such as thrombectomy, embolic protection devices, brachytherapy, or cutting balloons, was not allowed. Pre-and postprocedure dual antiplatelet therapy was recommended to conform to the American Heart Association/American College of Cardiology/Society for Cardiovascular Angiography and Interventions joint guidelines for PCI. 10 The primary safety end point of ORBIT II was the rate of 30-day major adverse cardiac events (MACEs) defined as the composite of cardiac death, MI, and target vessel revascularization (TVR). MI was defined as CK-MB >3x ULN with or without new pathologic Q waves. Rate of stent thrombosis was reported and defined according to the Academic Research Consortium definition. 11 All adverse events were adjudicated by an independent clinical events committee. All patients were followed clinically during the index hospitalization, at 30 days and at 1 year.
Continuous variables are summarized as mean AE SD. Survival curves for time-to-event variables were constructed on the basis of all available follow-up data using KaplanMeier methods. Multivariable Cox proportional hazards regression was performed to identify independent predictors of 1-year MACE and target vessel revascularization (TVR) (2-sided a ¼ 0.05 for significance). The multivariable model was built with candidate variables being selected if of clinical interest and/or satisfying the criterion of p <0.2 in the univariate analysis. Variables included in the final were carefully selected to avoid overfitting and included for MACE: age, previous coronary artery bypass graft surgery, estimated glomerular filtration rate, reference vessel diameter, lesion length, diameter stenosis, and use of baremetal stents (BMS) versus drug-eluting stents (DES), and for TVR: reference vessel diameter, diameter stenosis, and use of BMS versus DES. All statistical analyses were Values are n/N (%), mean AE standard deviation. * Total procedure time defined as the time from when the first guide catheter was placed in the access site to the time the last guide catheter was removed from the access site.
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Results

From
Coronary Artery Disease/ORBIT II Trial 1-Year Results
from 49 US sites were enrolled in the ORBIT II trial. Among them, 432 (97.5%) were actually treated with OAS before stent placement, and 1-year data were available in 433 patients (97.7%) (median follow-up time of 16.7 months). Baseline, angiographic, and procedural characteristics of the study population are listed in Table 1 . DES were implanted in most of the lesions treated (88.2% of stents).
At 1 year, the primary composite end point of MACE occurred in 16.4% of patients, with cardiac death occurring in 3.0%, MI in 9.7%, and TVR in 5.9% of patients ( Figure 1 , Table 2 ). The target lesion revascularization (TLR) rate was 4.7%, and only 1 (0.2%) stent thrombosis occurred within 1 year (Table 2) . When using the SCAI definition of periprocedural MI (CK-MB !10Â ULN without new Q waves or !5Â ULN with new Q waves), 12 the 1-year MI and MACE rates were 2.0% and 9.9%, respectively. Table 3 lists the rates of 1-year adverse clinical events stratified by stent type. Use of BMS was associated with a significantly higher rate of MACE, TVR, and TLR at 1 year.
Independent predictors of 1-year MACE and TVR are summarized in Table 4 . After multivariable analysis, diameter stenosis and the use of BMS emerged as independent predictors of MACE and TVR.
Discussion
The present study describes the long-term impact of treatment of severely calcified lesions using the novel and recently FDA-approved OAS. The main findings of the present study extend the favorable procedural and 30-day results previously reported 7 and demonstrate a relatively low rate of 1-year adverse ischemic events after treatment of this complex and high-risk cohort with OAS.
PCI of calcified lesions have been shown to be associated with a worse prognoses compared with lesions with no calcification.
1e3, 5, 6 Coronary calcification often leads to difficulty in delivering coronary devices, may damage the drug polymer and stent platform, 13 and limit full stent expansion, resulting in suboptimal procedural results and an increased risk of subsequent ischemic adverse events. Appropriate lesion preparation remains crucial to ensure optimal angiographic and clinical outcomes. However, despite improving procedural success and acute gain, the Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease (ROTAXUS) trial failed to demonstrate any clinical benefit of rotational atherectomy compared with standard balloon predilation for preparation of calcified lesions before DES implantation in regard to 9-month TVR (16.7% vs 18.3%, p ¼ 0.73), TLR (11.7% vs 12.5%, p ¼ 0.85), and MACE rates (defined as a composite of death, MI, and TVR; 24.2% vs 28.3%, p ¼ 0.46). 14 In contrast, the results with OAS in the present study are encouraging, with lower rates of TVR (5.9%), TLR (4.7%), and cumulative MACE (16.7%) at 1 year compared with historical controls, despite using a more stringent definition of severe coronary calcification as an enrolling criterion. Indeed, >90% of the treated lesions in the ORBIT II trial were considered severely calcified compared with w50% of the lesions enrolled in ROTAXUS.
14 Similarly, our results compared favorably with the recently published large pooled analysis from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction trials, showing TLR and MACE rates in patients with severe coronary calcification who underwent PCI being 8.7% and 19.9%, respectively. 1 That being said, ORBIT II was a single-arm trial with no direct comparator, and conclusions from indirect comparisons with different studies (including different patient populations, different stent types, etc.) should be considered hypothesis generating.
Given the angiographic complexity and high-risk profile of the ORBIT II population, the 1-year stent thrombosis rate is surprisingly low and compares favorably with previous studies. 15e17 Indeed, only 1 case (0.2%) of stent thrombosis occurred (at day 0, postprocedure). This finding is notable and may represent one of the most beneficial effects of OAS as an optimal tool in lesion preparation for severely calcified lesions. Angiographic lesion complexity and calcification have been identified as independent predictors of stent thrombosis, 1,18e20 with stent underexpansion being the most likely causal common denominator.
21e23 Although our findings are encouraging given the complexity of the lesions treated in ORBIT II, the relatively small number of patients enrolled in our study and the lack of a control arm preclude definitive conclusions regarding the utility of OAS to prevent stent thrombosis.
Several reasons could underlie the favorable long-term results seen in the present study. OAS uses a principle of off-axis centrifugal force, with the orbital motion diameter being proportional to the applied speed. This orbital movement results in sanding of the entire calcified wall and might allow for greater blood flow (nonocclusive) with less heat generation and thermal injury during the procedure compared with a potentially more aggressive and occlusive atherectomy approach. 24, 25 Additional imaging and mechanistic studies are required to determine the extent to which the unique mechanism of OAS contributes to the favorable outcomes observed in the present study.
Approximately 12% of the ORBIT II population underwent PCI of the target lesion with BMS during the index procedure. Not surprisingly, adverse ischemic event were higher in patients with BMS compared with DES, and the use of BMS was identified as an independent predictor of MACE and TVR. Reported previously, 26 this finding reiterates the dismal outcomes of BMS compared with DES when used in highly complex (i.e., heavily calcified) lesions. This finding also underlines the even more favorable results of lesion preparation using OAS, especially if only DES (specifically second generation) were used. 27 ORBIT II has important strengths. It is the first and largest prospective, multicenter trial including only patients with severe coronary calcification using strict angiographic enrolling criteria in the contemporary era of DES and potent antithrombotic agents. Indeed, ORBIT II enrolled patients typically excluded from standard clinical trials and still demonstrated outcomes comparable with trials excluding such patients. An independent angiographic core laboratory and independent clinical events committee reviewed and adjudicated all angiograms and adverse events. However, some limitations should be acknowledged. First, ORBIT II was a single-arm trial, with no control group. Therefore, extrapolation of the superiority of the OAS device compared with the standard strategy for treatment of severely calcified lesions could not be done. That being said, given that no device was FDA approved for treatment of calcified lesions at the time of conception of the trial, design of a head-to-head trial was deemed not necessary by the FDA. Second, adjunctive intracoronary imaging such as IVUS or optical coherence tomography was not mandated per protocol. Additional data from these imaging techniques would have been highly informative and could have provided insights on the therapeutic mechanisms and effects of OAS. 28, 29 Third, 49 sites randomized 443 patients, with a mean of w8 patients enrolled per site. Because the OAS device was a novel therapeutic tool and most of the investigators had no previous experience with this device, learning curve issues must be considered, and improved outcomes may be expected with increased operator experience.
